
    
      Consenting patients with self-reported neuropathy following either diabetes or administration
      of chemotherapy, will undergo sensory testing and skin biopsies of the the foot and leg prior
      to initiating treatment. They will undergo PBM 3 times weekly for 6 weeks with with a
      follow-up biopsy performed at the conclusion of therapy and sensory testing throughout.
      Patients will have one remote evaluation at 26 weeks to determine whether the effect, if any
      extinguishes.
    
  